The question for Lilly, and for every innovator playing in India's weight-loss drug sector is: How much of the global model needs to be rebuilt for a market where innovation opens the door, but price decides who walks through it?
Train Both Clinical and Non-Clinical Team Members Give injectors and clinical staff detailed protocol training, including screening and documentation
Standardized dosing protocols, validated outcome measures, and comprehensive safety monitoring would establish the evidence base necessary for informed clinical decision-making
Another possible explanation for increased fertility from weight-loss medication is the way the GLP-1 receptor agonists, which is a class of drugs including Ozempic, Wegovy and others, work
Innovent holds the marketing rights for mazdutide in China, while Eli Lilly retains outside China global development rights, marking the program as a high-profile partnership
Weight loss typically improves lipid profiles, but monitoring confirms this
